216 related articles for article (PubMed ID: 18519754)
1. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.
Woloszynska-Read A; Mhawech-Fauceglia P; Yu J; Odunsi K; Karpf AR
Clin Cancer Res; 2008 Jun; 14(11):3283-90. PubMed ID: 18519754
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
[TBL] [Abstract][Full Text] [Related]
3. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
7. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract][Full Text] [Related]
8. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
[TBL] [Abstract][Full Text] [Related]
9. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Oi S; Natsume A; Ito M; Kondo Y; Shimato S; Maeda Y; Saito K; Wakabayashi T
J Neurooncol; 2009 Mar; 92(1):15-22. PubMed ID: 19030781
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
[TBL] [Abstract][Full Text] [Related]
12. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
Vaughan HA; Svobodova S; Macgregor D; Sturrock S; Jungbluth AA; Browning J; Davis ID; Parente P; Chen YT; Stockert E; St Clair F; Old LJ; Cebon J
Clin Cancer Res; 2004 Dec; 10(24):8396-404. PubMed ID: 15623618
[TBL] [Abstract][Full Text] [Related]
15. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
16. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
de Carvalho F; Vettore AL; Inaoka RJ; Karia B; Andrade VC; Gnjatic S; Jungbluth AA; Colleoni GW
Cancer Immun; 2011 Jan; 11():1. PubMed ID: 21247062
[TBL] [Abstract][Full Text] [Related]
18. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]